医学
肝细胞癌
药品
内科学
阶段(地层学)
肝癌
癌症
肿瘤科
胃肠病学
药理学
生物
古生物学
作者
JooSeok Song,Do Young Kim
出处
期刊:World Journal of Hepatology
日期:2017-01-01
卷期号:9 (18): 808-808
被引量:83
标识
DOI:10.4254/wjh.v9.i18.808
摘要
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEB-TACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.
科研通智能强力驱动
Strongly Powered by AbleSci AI